PDPA vs FDA 21 CFR Part 11
PDPA
Singapore regulation governing personal data protection
FDA 21 CFR Part 11
FDA regulation for electronic records/signatures equivalence to paper.
Quick Verdict
PDPA governs personal data protection in Asia for all organizations, mandating consent and breach reporting. FDA 21 CFR Part 11 ensures electronic records' trustworthiness in life sciences via validation and audit trails. Companies adopt PDPA for privacy compliance, Part 11 for FDA-regulated digital equivalence.
PDPA
Singapore Personal Data Protection Act 2012
Key Features
- Mandatory Data Protection Officer appointment
- Principles-based framework balancing privacy and business
- Deemed consent with notification for flexibility
- 72-hour breach notification for significant harm
- Do Not Call Registry for marketing
FDA 21 CFR Part 11
21 CFR Part 11: Electronic Records; Electronic Signatures
Key Features
- Secure, time-stamped audit trails for changes
- System validation ensuring accuracy and reliability
- Electronic signatures equivalent to handwritten
- Access, authority, and device checks
- Risk-based controls for open/closed systems
Detailed Analysis
A comprehensive look at the specific requirements, scope, and impact of each standard.
PDPA Details
What It Is
Singapore’s Personal Data Protection Act 2012 (PDPA) is a principles-based regulation for private sector organizations handling personal data. It governs collection, use, disclosure, balancing individual privacy rights with business needs via risk-based obligations like consent, protection, and accountability.
Key Components
- **9 core obligationsconsent/notification, access/correction, accuracy, protection, retention limitation, transfer limitation, accountability, breach reporting, Do Not Call provisions.
- Mandatory DPO appointment and Data Protection Management Programme (DPMP).
- Built on reasonableness and proportionality principles.
- Compliance demonstrated through policies, audits, no formal certification.
Why Organizations Use It
- Legal mandate avoids fines up to SGD 1 million or 10% revenue.
- Enhances breach readiness, risk management.
- Builds customer trust, enables data innovation.
- Supports partnerships, competitive edge in digital economy.
Implementation Overview
- **Phased approachgovernance/DPO setup, data mapping/DPIAs, controls/training, monitoring.
- Applies to all Singapore organizations processing personal data.
- Focus on operational maturity via PDPC guidance, self-assessments.
FDA 21 CFR Part 11 Details
What It Is
FDA 21 CFR Part 11 is a U.S. regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using computerized systems for predicate rule records. The approach is risk-based, with narrowed scope per 2003 FDA guidance and enforcement discretion for certain controls.
Key Components
- **SubpartsGeneral provisions, electronic records (closed/open systems controls), electronic signatures.
- Core controls: validation, audit trails, access limits, operational/authority/device checks, training, accountability policies, signature linking/uniqueness.
- Built on ALCOA+ principles; no certification, but compliance via validation and inspection readiness.
Why Organizations Use It
- Meets predicate rule requirements for pharmaceuticals, devices, biologics.
- Mitigates data integrity risks, avoids warning letters.
- Enables digital transformation, improves efficiency, audit trails for investigations.
- Builds regulator trust, supports global harmonization (e.g., EU Annex 11).
Implementation Overview
- **Phasedscoping, gap analysis, validation (IQ/OQ/PQ), SOPs/training, ongoing monitoring.
- Targets life sciences; risk-based CSV per GAMP5.
- No formal certification; FDA inspections verify compliance.
Key Differences
| Aspect | PDPA | FDA 21 CFR Part 11 |
|---|---|---|
| Scope | Personal data protection across collection, processing, transfers | Electronic records/signatures trustworthiness and equivalence |
| Industry | All sectors in Singapore/Thailand/Taiwan, regional focus | Life sciences, pharma, devices, US-regulated products |
| Nature | Mandatory national privacy regulations with fines | FDA regulation for electronic records, enforcement discretion |
| Testing | Risk assessments, security measures, no formal validation | System validation (IQ/OQ/PQ), audit trails required |
| Penalties | Fines up to SGD1M/THB5M, criminal sanctions | Warning letters, product holds, enforcement actions |
Scope
Industry
Nature
Testing
Penalties
Frequently Asked Questions
Common questions about PDPA and FDA 21 CFR Part 11
PDPA FAQ
FDA 21 CFR Part 11 FAQ
You Might also be Interested in These Articles...

Proving CIS Controls v8.1 Works: A KPI & Evidence Framework for Board Reporting, Audits, and Continuous Assurance
Prove CIS Controls v8.1 effectiveness with KPI catalog, evidence checklist & reporting cadence. Ideal for board reports, audits & cyber-insurance. Measure outco

Cyber Essentials on a Shoestring: Filling the Microsoft 365 Security Gaps with Free and Low-Cost Tools
Close Cyber Essentials 2026 gaps in basic Microsoft 365 plans using free and low-cost tools. Achieve MFA, patching, and audit readiness without enterprise spend

Top 10 Reasons CMMC Level 3 Certification Unlocks Competitive Edge for Primes Handling Critical DoD Programs
Discover top 10 reasons CMMC Level 3 certification unlocks competitive edge for DoD primes. Reduced APT risks, procurement prefs, NIST 800-172 compliance via v2
Run Maturity Assessments with GRADUM
Transform your compliance journey with our AI-powered assessment platform
Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.
Explore More Comparisons
See how PDPA and FDA 21 CFR Part 11 compare against other standards